There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amarin (AMRN), Pluristem (PSTI) and Biospecifics Technologies Corp (BSTC) with bullish sentiments.
Amarin (AMRN)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Amarin, with a price target of $51. The company’s shares closed on Friday at $21.05, close to its 52-week high of $23.34.
Fein commented:
“We believe that beyond the topline of 25% reduction of MACE score, the robustness of the data is highlighted by the consistency across pre-specified analyses. A key secondary composite, namely 3-point MACE score (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), which assesses the major CV events (and reflects the most important clinical relevance), showed an even higher reduction of risks at 26% compared to placebo. The clinical benefits as measured by the primary endpoint of MACE score and the key secondary 3-point MACE score are observed across subgroups (statistically significant in the vast majority of the subgroups), which speaks to the validity and robustness of the data.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 11.2% and a 44.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amarin with a $30.80 average price target, representing a 46.3% upside. In a report issued on November 8, Jefferies also initiated coverage with a Buy rating on the stock with a $30 price target.
.
See today’s analyst top recommended stocks >>
Pluristem (PSTI)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Pluristem, with a price target of $3.50. The company’s shares closed on Friday at $1.19.
According to TipRanks.com, Ramakanth is a 2-star analyst with an average return of 0.7% and a 34.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pluristem with a $3.25 average price target, which is a 173.1% upside from current levels. In a report issued on November 8, Maxim Group also maintained a Buy rating on the stock with a $3 price target.
.
Biospecifics Technologies Corp (BSTC)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Biospecifics Technologies Corp, with a price target of $81. The company’s shares closed on Friday at $57.96.
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.9% and a 28.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Fennec Pharmaceuticals Inc, and Aerpio Pharmaceuticals Inc.
Currently, the analyst consensus on Biospecifics Technologies Corp is a Moderate Buy with an average price target of $81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
